Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

3121 PWToday Stories

Allergan Announces Settlement of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation with Famy Care

31 Aug 17

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and its subsidiaries today announced that it has reached a settlement regarding its litigation with Famy Care Limited relating to Allergan's United States Patent Nos. 8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,930 and 9,248,191 covering RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%. The patents are listed in the Orange Book and expire on August 27, 2024.

As a result of the settlement, all Famy Care litigation regarding RESTASIS® patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review. Allergan will grant Famy Care a license to market a generic version of RESTASIS® in the United States beginning on February 27, 2024, or earlier under certain circumstances. Additional details regarding the settlement were not disclosed.

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.